683 Capital Management’s Harmony Biosciences HRMY Stock Holding History

683 Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$412K	Buy	+14,700	New	+$482K	0.02%	197

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

683 Capital Management's HRMY Position: Q1 2026 in Review

683 Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 415,000 shares — an estimated $13.6M sold.

683 Capital Management first reported a position in HRMY in Q1 2023 and held it in 12 quarters. The position peaked at $15.5M in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

683 Capital Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
683 Capital Management sold 415,000 Harmony Biosciences shares in Q1 2026, an estimated $13.6M.
683 Capital Management first reported a position in Harmony Biosciences in Q1 2023 and held it in 12 quarters.
683 Capital Management's Harmony Biosciences position peaked at $15.5M in Q4 2025.
309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.